Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

Exclusion Criteria

• •Previous treatment with Glucagon Like Peptide-1 analogues or insulin in the past year (except in case of temporary treatment for gestational diabetes, surgery, hospitalization...),
• •Treatment with thiazolidinediones or α-Glucosidases inhibitors within 3 months prior to study entry,
• •Diabetes other than Type 2 diabetes (e.g. secondary to pancreatic disorders, drug or chemical agents intake),
• •Pregnant women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method),
• •Lactating women,
• •Hospitalized patients (except hospitalization for routine diabetes check-up),
• •Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to study entry, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study, documented by a retina examination within 2 years prior to study entry,
• •Impaired renal function (creatinine clearance \< 60 mL/mn),
• •Impaired hepatic function (Alanine Aminotransferase, Aspartate Aminotransferase 2.5 times the upper limit of normal range),
• •Personal or family history of medullary thyroid carcinoma,
• •Multiple endocrine neoplasia syndrome type 2,
• •Severe gastro-intestinal disease (including inflammatory bowel disease or diabetic gastroparesis),
• •Congestive heart failure,
• •History of acute pancreatitis,
• •Treatment with corticosteroids with potential systemic action for more than 10 days within 3 months prior to study entry,
• •Alcohol or drug abuse in the past 5 years,
• •History of sensitivity to the study drugs or to drugs with a similar chemical structure.
• •Night shift worker,
• •Presence of any condition (medical, psychological, social or geographical), current or anticipated that would compromise the patients safety or limit the patient successful participation in the study,
• •Participation in a clinical trial (drug or device) within 3 months prior to study entry,
• •Refusal or inability to give informed consent to participate in the study,
• •Patient is the Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
• •Treatment with oral antidiabetic drugs other than metformin and patient's usual sulfonylurea if any, or with insulin during the comparative period (except in case of an emergency, for a period of time less than 7 days),
• •Treatment with corticosteroids with potential systemic action within the last 3 months of the comparative period.
• •History of sensitivity to insulin glargine.